beyfortus
astrazeneca ab - nirsevimab - immunoseerumit ja immunoglobuliinit, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiset aineet - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
mysoline 250 mg tabletti
astrazeneca oy - primidonum - tabletti - 250 mg - primidoni
citanest 10 mg/ml injektioneste, liuos
astrazeneca oy - prilocaini hydrochloridum - injektioneste, liuos - 10 mg/ml - prilokaiini
xylocain 5 % voide
astrazeneca oy - lidocainum - voide - 5 % - lidokaiini
xylocain 5 mg/ml kurlausvesi
astrazeneca oy - lidocaini hydrochloridum - kurlausvesi - 5 mg/ml - lidokaiini
fulcin 125 mg tabletti
astrazeneca uk limited - griseofulvinum - tabletti - 125 mg - griseofulviini
avlosulfon 100 mg tabletti
astrazeneca uk limited - dapsonum - tabletti - 100 mg - dapsoni
ekvacillin injektio/infuusiokuiva-aine, liuosta varten
astrazeneca oy - cloxacillinum natricum - injektio/infuusiokuiva-aine, liuosta varten - kloksasilliini
inderal 1 mg/ml injektioneste
astrazeneca uk limited - propranololi hydrochloridum - injektioneste - 1 mg/ml - propranololi